Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes
Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes
This is a non-randomized, single-case design of pharmacogenetic implementation in a mental
 health patient population of subjects taking antipsychotics and/or antidepressants.
This is a non-randomized, single-case design of pharmacogenetic implementation in a mental
 health patient population of subjects taking antipsychotics and/or antidepressants.
 Retrospective and prospective data will be collected on all subjects before and after
 pharmacogenetic recommendations have been made. Retrospective data will be collected for the
 previous 12 months before pharmacogenetic recommendations are made and prospective data will
 be collected for 12 months after pharmacogenomic recommendations have been made.
Inclusion Criteria:

 -  Must be taking either an anti-depressant or an anti-psychotic medication

 -  Must provide informed consent

 -  Must have Avera Health Plans insurance coverage

 -  Must have three months of participation in the Avera Care Coordination Program

 Exclusion Criteria:

 -  Must not be pregnant or breastfeeding

 -  Must not have an active and/or unstable diagnosis of substance abuse

 -  Must not have a primary diagnosis of dementia, bulimia, or anorexia nervosa disorder

 -  Must not have had a previous pharmacogenetic evaluation